Fragments of fibronectin occur naturally in i o and are increased in the synovial fluid of arthritis patients. We have studied the 45 kDa fragment (Fn-f 45), representing the N-terminal collagenbinding domain of fibronectin, for its ability to modulate the expression of metalloproteinases by porcine articular chondrocytes in itro. We report that stimulation of cultured chondrocytes, or cartilage explants, with Fn-f 45 increased the levels of matrix metalloproteinase-13 (MMP-13; collagenase-3) released into the conditioned medium in a dose-dependent manner. Increased levels of MMP-13 were due to stimulation of MMP-13 synthesis, rather than release of MMP-13 from accumulated matrix stores. Fn-f 45 also stimulated the synthesis of MMP-3 (stromelysin-1) from cultured chondrocytes and cartilage cultures. The Fn-f 45-induced increase in MMP-3 and MMP-13 synthesis occurred via an interleukin 1-independent mechanism, since the receptor antagonist of interleukin-1 was unable to block the increased synthesis. The gelatinases, MMP-2
INTRODUCTION
Fibronectin is an extracellular matrix glycoprotein found in low levels in most body fluids and connective tissues, with elevated expression associated with tissues undergoing remodelling or repair. It is a disulphide-bonded dimer that occurs as different isoforms due to alternative splicing of the primary transcript, including a cartilage-specific isoform ( Figure 1 ). Distinct functional domains of fibronectin have been identified, with a welldocumented integrin-binding site mapped to the central cellbinding domain and regions that interact with matrix molecules, such as collagen, heparin and fibrin mapped to the N-terminal domain ( Figure 1 ). Fibronectin is of particular interest in the study of arthritis, because it is now clear that proteolytic fragments of fibronectin exhibit biological properties that are distinct from the intact molecule, suggesting that proteolysis leads to the release of cryptic activities (for a review see [1] ).
Fibronectin is a minor component of healthy cartilage; however, elevated levels are present in arthritis, associated with cartilage, the synovial fluid and the surface of the synovium. This accumulation is probably due to increased synthesis of fibronectin, as well as an increased capacity for damaged cartilage to bind fibronectin [1] . Significantly, it has been estimated that up to 50 % of the fibronectin in arthritic synovial fluids has been proteolytically fragmented, with fragments (Fn-fs) of 30-200 kDa reported [2, 3] . The importance of Fn-fs in cartilage catabolism is Abbreviations used : ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs ; APMA, 4-aminophenylmercuric acid ; CM, conditioned media ; DMEM, Dulbecco's modified Eagle's medium ; FCS, fetal calf serum ; Fn-f 29, 29 kDa N-terminal heparin-binding domain of fibronectin ; Fn-f 45, 45 kDa collagen-binding domain of fibronectin ; G1, G2, G3, globular domains of aggrecan ; GdmCl, guanidinium chloride ; IL-1α, interleukin-1α ; IL-1Ra, interleukin-1 receptor antagonist ; MMP, matrix metalloproteinase ; tTG, tissue transglutaminase. 1 To whom correspondence should be addressed (e-mail fosang!cryptic.rch.unimelb.edu.au).
and MMP-9, were not modulated by Fn-f 45 in these culture systems. Fn-f 45 also stimulated the release of aggrecan from cartilage explants into conditioned medium. Neoepitope antibodies specific for aggrecan fragments generated by MMPs or aggrecanases showed that the Fn-f 45-induced aggrecan loss was mediated by aggrecanases, and not by MMPs. Extracts of cultured cartilage contained elevated levels of the aggrecanasederived ITEGE$($-G1 domain, whereas levels of the matrix metalloproteinase-derived DIPEN$%"-G1 domain were unchanged. These studies show that Fn-f 45 can induce a catabolic phenotype in articular chondrocytes by up-regulating the expression of metalloproteinases specific for the degradation of collagen and aggrecan.
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demonstrated by studies in i o showing that injection of a 29 kDa N-terminal heparin-binding domain of Fn-f (Fn-f 29) into rabbit knee joints causes severe depletion of proteoglycan within days [4] . Fn-f 29, and Fn-fs encompassing the collagenbinding domain and the cell-binding domain (Figure 1 ), have been shown to promote loss of cartilage proteoglycan in itro [5] . Although there is some evidence to suggest that select Fn-fs may possess intrinsic proteolytic activities [6, 7] , most reports suggest that Fn-f-induced cartilage degradation is due to increases in metalloproteinase expression and activity. Fn-f 29 can stimulate the release of several matrix metalloproteinases (MMPs) from cartilage explants in culture, including MMP-3 (stromelysin-1) and MMPs-2 and -9 (gelatinases A and B respectively) [8] , whereas peptides from the cell-binding domain of fibronectin increase MMP-3 synthesis by chondrocytes [9] . Enhanced metalloproteinase expression may well be a consequence of Fnf-induced increases in catabolic cytokines. Fn-f 29 at micromolar concentrations stimulated the release of interleukin-1, tumour necrosis factor-α and interleukin-6, concurrent with the degradation of proteoglycan in itro [8] . Curiously, at nanomolar concentrations Fn-f 29 promoted cartilage repair, stimulating proteoglycan synthesis and release of the anabolic factors transforming growth factor-β and insulin-like growth factor-1 [10] . Possibly the switch from Fn f-induced anabolic response to catabolic response occurs as Fn-fs accumulate in arthritic tissue.
Figure 1 Schematic representation of fibronectin and its fragments
An isoform of human fibronectin specific to cartilage is depicted [48] . The diagram shows one arm of the fibronectin dimer, which is linked by disulphide bonds. Fn-f 45, used in the present study, consists of type I and type II repeating units and contains the gelatin-and collagenbinding domains. Other studies have focused on Fn-f 29 and the 110-140 kDa cell-binding domain containing the major integrin-binding site [1] .
There is extensive literature describing increased levels of local MMP expression in human and animal joint disease, and in culture models in itro. Stromelysin-1 (reviewed in [11] ) and the collagenases, particularly collagenase-3 ( [12] [13] [14] and references therein), have received the most attention for their putative roles in cartilage destruction in arthritis. These soluble MMPs are secreted as zymogens that are maintained in a latent form by the N-terminal propeptide domain, and become active upon exposure of the catalytic site. Although a number of biochemical reactions can activate MMPs in itro [15] , in i o the primary activation mechanisms are thought to be by proteolytic removal of the propeptide domain. Once activated, MMPs are regulated further by binding of the endogenous tissue inhibitors of metalloproteinases (' TIMP's).
The destruction of cartilage in arthritic disease is largely due to proteinase attack on the major structural molecules, type II collagen and aggrecan. In its native fibrillar form, the triple helix of type II collagen is susceptible to cleavage by the collagenase subfamily of MMPs (MMP-1, MMP-8 and MMP-13) and membrane type-1 MMP (MMP-14) [16] . Chondrocytes express all three collagenases and MT1-MMP, but MMP-13 is thought to be the main enzyme involved in type II collagen degradation, because it cleaves this substrate significantly faster than the other collagenases [12] , and because its tissue distribution is limited to cartilage and bone in normal tissues.
Aggrecanolysis occurs early in cartilage damage, and has been attributed to the ' aggrecanases ' [17, 18] and the MMPs (reviewed in [19] ). The aggrecanases are members of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin repeats) family of proteinases and are characterised by their N-terminal metalloproteinase and disintegrin-like motifs, and various numbers of thrombospondin type I motifs at the C-terminus (reviewed in [20] ). Importantly, ADAMTS enzymes possess a consensus sequence recognized by furin convertases, so activation of these enzymes is likely to occur during secretion, unlike the MMPs that are mainly activated extracellularly. Neoepitope antibodies specific for MMP-or ADAMTS-degraded aggrecan fragments distinguish between these activities in i o [19] . Anti-DIPEN$%" and anti-F$%#FGVG antibodies detect MMP cleavage in the aggrecan interglobular domain, whereas anti-ITEGE$($ and anti-A$(%RGSV antibodies identify ADAMTS cleavage in the same region. Neoepitope antibodies recognizing fragments derived from the chondroitin-sulphate region have also been used in studies in itro to monitor cleavage site preferences for ADAMTS-4 [21] .
In the present paper, we describe work with Fn-f 45 (45 kDa collagen-binding domain of fibronectin; see Figure 1 ). This domain has received less attention in the literature, however, it has been shown recently to bind cell-surface tissue transglutaminase, and has the potential to signal via integrins [46] . We show that Fn-f 45 induces the expression of MMPs-13 and -3 and ADAMTS activity. Our results suggest that Fn-f 45 may have an important role in the catabolism of cartilage matrix in arthritic disease. [22] and polyclonal rabbit sera specific to the C-terminal sequence DIPEN$%" and the C-terminal sequence ITEGE$($ [23] were as described. The sheep polyclonal antibodies against human MMP-3 [24] and human MMP-13 [25] were gifts from Professor G. Murphy and Dr V. Kna$ uper. These antibodies cross-react with their corresponding pig antigens. A second sheep polyclonal antibody to human MMP-3, kindly provided by Professor H. Nagase (Kennedy Institute of Rheumatology, Hammersmith, The 45 kDa fibronectin fragment induces MMP-13 synthesis and aggrecanase activity London, U.K.), was used to confirm the molecular mass of porcine MMP-3.
EXPERIMENTAL Materials

Methods
Chondrocyte culture
Articular cartilage was dissected from the metacarpophalangeal joint of pigs aged 25-28 weeks. The cartilage was washed twice with PBS and digested overnight with bacterial collagenase (2 mg\ml) in Ham's F-12 medium, containing 5 % (v\v) FCS, 100 units\ml penicillin, 100 µg\ml streptomycin and 2 mM glutamine. The digest was then passed through a 70 µm cell strainer to separate chondrocytes from undigested tissue debris. Chondrocytes were washed three times in DMEM\10 % (v\v) FCS [DMEM containing 10 % (v\v) FCS, 100 units\ml penicillin, 100 µg\ml streptomycin and 2 mM glutamine] and the cell viability was assessed using Trypan Blue. Cells were seeded at high density (0.68i10' cells\cm#) to maintain the chondrocytic phenotype and cultured in DMEM\10 % (v\v) FCS in a humidified incubator in 5 % (v\v) CO # at 37 mC. After 48 h, the medium was changed to serum-free DMEM, and the chondrocytes were cultured for a further 18 h. The medium was then changed to fresh serum-free DMEM, containing 0.01-1 µM Fn-f or 10 ng\ml IL-1. IL-1 receptor antagonist (IL-1Ra) protein (10 µg\ml) was added to some cultures. After a 48 h incubation, the chondrocyte conditioned media (CM) were harvested and stored at k20 mC. All experiments involved treatment of cells in triplicate wells. Each experiment was repeated a minimum of three times, with the number of repeats for specific observations indicated in the text. Representative results are shown.
Immunolocalization
Freshly isolated chondrocytes were seeded as high-density monolayers in eight-well Permanox slides and cultured as described above. Cells were stimulated with either IL-1α (10 ng\ml) or Fnf 45 (1 µM) for 24 h only. The ionophore monensin was added to the cultures at 5 µM for the last 5 h to prevent the secretion of newly synthesized proteins. Cells were fixed with freshly prepared formaldehyde (5 min at room temperature). The fixative was then removed by washing the cells in PBS (three times for 5 min each). Cells were permeabilized for 5 min at room temperature with 0.1 % Triton X-100 in PBS, washed as described above and stained by indirect immunofluorescence using sheep anti-human MMP-13 or sheep anti-human MMP-3 [50 µg\ml in PBS containing 5 % (v\v) normal donkey serum]. Following washing, the cells were incubated with FITC-labelled donkey anti-sheep IgG (1 : 200 dilution). All antibodies were diluted in PBS with 1 % BSA. The cells were mounted in Vectashield, and viewed by epifluorescence on an Olympus IX70 inverted microscope, with narrow-band FITC filter set, photographed on Eastman Kodak Co. EPH P1600 film.
Cartilage explant culture
Explants of articular cartilage dissected from the metacarpophalangeal joints of pigs (25-28 weeks old) were cultured as described previously [26] . Briefly, explants were cultured for 5 days in serum-free DMEM containing 100 units\ml penicillin and 100 µg\ml streptomycin, 2 mM -glutamine and 20 mM Hepes. Each culture well contained approx. 100 mg of cartilage in 500 µl of medium. CM were collected daily, frozen for further analysis, and replaced with fresh medium. Treatments commenced on day 3, and treated cartilage received 10 ng\ml IL-1α, or 0.01-1 µM Fn-f, for days 3, 4 and 5 of the culture period. 
Guanidinium chloride (GdmCl) extraction and papain digestion of cartilage
At the end of the culture period, aggrecan and aggrecan fragments enriched in the G1 globular domain were extracted from tissue using 4 M GdmCl\50 mM sodium acetate\10 mM EDTA, pH 5.8 (1 ml). Tissue was extracted over a 48 h period at 4 mC and then extracts were dialysed exhaustively against distilled water containing 10 mM EDTA and freeze dried for later analysis. The tissue remaining after GdmCl extraction was rinsed twice with PBS and digested overnight at 60 mC with 1 ml of papain solution containing 125 µg\ml papain, 0.1 M sodium acetate, pH 5.5, 5 mM EDTA and 5 mM cysteine-HCl.
Dye binding assay
Aliquots of CM, GdmCl extracts and papain digests were assayed for sulphated glycosaminoglycan by the 1,9-Dimenthyl-Methylene Blue assay [27] . Total glycosaminoglycan\well was calculated as the sum of glycosaminoglycan contained in the CM, GdmCl extracts and papain digests.
Western blot analyses of MMP-13 and MMP-3
Aliquots of CM from chondrocyte cultures, or media collected daily from cartilage explant cultures, were separated under reducing conditions on 10 % SDS\PAGE gels. Proteins were transferred to PVDF membranes and probed with polyclonal antibodies against MMP-13 or MMP-3. Bound antibody was detected using a horseradish-peroxidase-conjugated secondary antibody, followed by enhanced chemiluminescence. Bands on Western blots were analysed by densitometry, using a Bio-Rad GS-800 densitometer with Quantity One Version 4.2.1 software.
Zymography
CM were analysed for gelatin-degrading activity by electrophoresis under non-reducing conditions on SDS\7 % polyacrylamide gels, containing 0.5 mg\ml gelatin [28] . The gels were incubated overnight at room temperature in 100 mM Tris\HCl, pH 7.9\30 mM CaCl # \0.02 % (w\v) azide. Staining with Coomassie Brilliant Blue revealed clear zones of lysis, indicating gelatin-degrading activity. Under the conditions used for zymography, there was no apparent contamination of the Fn-f 45 preparations with gelatinases [29] .
Activation of MMPs
MMPs in CM were activated by treatment with the organomercurial APMA. CM were incubated with 2 mM APMA for 6 h at 37 mC. Activation was stopped by the addition of gelloading buffer.
Composite gel electrophoresis and AF-28 Western blotting
Cartilage CM were analysed for whole aggrecan and aggrecan fragments comprising a $%#FFGVG N-terminus by composite gel electrophoresis, using 0.6 % (w\v) agarose\1.2 % (w\v) acrylamide gels [30] . Media samples from each day of culture containing equal amounts of sulphated glycosaminoglycan were separated on composite gels. Duplicate gels were either stained with Toluidine Blue, or transferred to PVDF membrane for Western blotting, using AF-28 antibody. Bound antibody was detected using a peroxidase-conjugated secondary antibody, followed by enhanced chemiluminescence.
Analysis of DIPEN and ITEGE G1 fragments
The G1 aggrecan fragments extracted from cartilage by 4 M GdmCl were treated with keratanase-1 and chondroitinase ABC before electrophoresis. Extracts were incubated overnight at 37 mC in 50 mM Tris acetate buffer, pH 7.2, with 0.005 unit of keratanase-1 and 0.005 unit of chondroitinase ABC in the presence of 10 mM EDTA, 20 µg\ml trans-epoxysuccinyl--lencylamido-(4-guanido)butane (E64), 5 µM pepstatin and 1.25 mM 4-(2-aminoethyl)benzene sulphonylfluoride. Samples for DIPEN$%" and ITEGE$($ analyses were loaded on SDS\5 % polyacrylamide gels and separated under non-reducing conditions (DIPEN$%") or reducing conditions (ITEGE$($). Blots were probed with polyclonal antibodies against the DIPEN$%" and ITEGE$($ neopitopes, followed by a peroxidase-conjugated secondary antibody and chemiluminescent substrate detection.
Standardization of gel loadings
Conditioned media analyses. For composite gel analyses of soluble aggrecan fragments, gels were loaded on the basis of equal sulphated glycosaminoglycan in the medium. This allows a comparison of the proportion of aggrecan fragments released between samples. However, for analyses of secreted MMPs, it was more appropriate to load CM samples on the basis of total tissue weight, or total sulphated glycosaminoglycan, because the two are proportional. GdmCl extract analyses. For DIPEN$%" and ITEGE$($ epitope analyses, GdmCl extracts were loaded on the basis of total tissue weight, or total sulphated glycosaminoglycan per well, because the majority of these fragments lack sulphated glycosaminoglycans and remain in the tissue.
RESULTS
Fn-f 45 induces the synthesis and secretion of MMP-13 and MMP-3 by chondrocytes
To investigate the effects of Fn-f 45 on the expression of MMP-13 by chondrocytes, pig articular chondrocytes were cultured in high-density monolayers and treated with Fn-f 45 for 48 h under serum-free conditions. CM were examined for MMP-13 expression by Western blotting. when added at similar protein concentrations. MMP-13 in the CM was increased by 0.1 µM Fn-f 45 ( Figure 2B ), and maximally increased by 0.5 µM. These concentrations of Fn-f 45 are within the concentration range estimated for Fn-f in osteoarthritic synovial fluids [3] , and predicted for Fn-f in osteoarthritic cartilage [31] .
To confirm that the MMP-13 detected was in the latent form, a CM sample was incubated with the organomercurial activator APMA. Western blot analysis showed that APMA treatment caused a shift in the molecular mass of the MMP-13, cor- responding to the stepwise loss of the propeptide. Pro-, intermediate and fully active MMP-13 were detected in the APMA-treated sample ( Figure 2C ), confirming that MMP-13 in the untreated CM was in the latent form. The APMAactivated MMP-13 (pig) co-migrated with active human recombinant MMP-13 (results not shown). In all experiments with isolated chondrocytes, the MMP-13 was detected in the latent form.
Fn-f 45 also stimulated the expression of MMP-3, detected by Western blotting ( Figure 3A ). Densitometric analysis of three experiments indicated that levels of MMP-3 were 5-20-fold greater in Fn-f 45-treated cultures than in control cultures, compared with increases of 3-13-fold, in IL-1α-treated cultures. Pig MMP-3 secreted into the CM had an apparent molecular mass of 66 kDa, which is higher than that reported for human MMP-3 [32] . Deglycosylation of pig MMP-3 with N-glycosidase led to a drop in molecular mass of 6 kDa, indicating that pig MMP-3 contains N-linked oligosaccharides. Pig MMP-3 would occasionally resolve as a doublet, similar to the human enzyme. The 66 kDa form of pig MMP-3 corresponded to the latent enzyme, since incubation of the CM with APMA caused a drop in molecular mass of approx. 12 kDa, indicating a loss of the propeptide ( Figure 3B) .
The increased levels of MMP-13 and MMP-3 enzymes in the CM in response to Fn-f 45 could reflect increased enzyme synthesis, or increased release of the enzymes from matrix-bound stores. To determine whether Fn-f 45 stimulated synthesis of MMP-13 or MMP-3, chondrocytes were treated with Fn-f 45 for 24 h and the ionophore monensin was added for the final 5 h of culture. Monensin caused the intracellular accumulation of newly synthesized MMPs, which were detected by immunolocalization. Since IL-1α has been shown to increase MMP-13 synthesis by chondrocytes [12] , IL-1α treatment was included as a positive control. Figure 4 shows that in comparison with the untreated control cells, IL-1α treatment caused a marked increase in detectable MMP-13 (compare Figure 4C with 4A) and MMP-3 (compare Figure 4D with 4B) . Staining for MMPs was both intracellular and associated with the matrix. In Fn-f 45-treated cultures, prominent staining of MMP-13 and MMP-3 in selected cells was associated with a discrete juxtanuclear lamellar structure, most likely the Golgi apparatus ( Figure 4 , panels E and F respectively; see arrows). The levels of matrix-bound MMP-13 and MMP-3 were also higher in Fn-f 45-treated cultures ( Figure  4E and 4F). Cultures stained with normal sheep serum showed background levels similar to those of the control cultures (compare Figures 4G and 4A ). The data indicate that Fn-f 45 does act to increase the synthesis of MMP-13 and MMP-3.
Induction of MMP-13 and MMP-3 expression is not via an IL-1 autocrine loop
Several studies have shown that fragments of fibronectin increase MMP expression via an IL-1 autocrine loop. One study has demonstrated that peptides encompassing the RGD integrinbinding sequence of fibronectin increase MMP-3 synthesis by chondrocytes via IL-1 [9] . Similarly, Fn-f 29-induced MMP-3 synthesis by human cartilage in culture can be partially blocked by neutralizing antibodies against IL-1 [10] . In the current study, the hypothesis that Fn-f 45 increases MMP-13 and MMP-3 synthesis via an IL-1 autocrine loop was investigated using IL1Ra to competitively inhibit IL-1 interaction with its receptor. First, to determine the amount of antagonist required to inhibit MMP expression stimulated by exogenously added IL-1α, varying concentrations of IL-1Ra were added to chondrocyte cultures stimulated with IL-1α at 10 ng\ml. Although a concentration of 100 ng\ml IL-1Ra was effective at reducing IL-1α-induced MMP-13 to basal levels, we chose to use 10 µg\ml IL-1Ra to ensure that all endogenous IL-1 would be inhibited. Figure 5 shows that 10 µg\ml IL-1Ra reduced IL-1α-stimulated MMP-13 synthesis to control levels [ 
Fn-f 45 regulates the expression of MMP-13 and MMP-3 by cartilage explants
To follow on from the studies with isolated chondrocytes in culture, we used a cartilage culture model to determine whether
Figure 5 IL-1Ra protein does not inhibit Fn-f 45-induced synthesis of MMP-13 or MMP-3
Chondrocytes were cultured for 48 h in serum-free medium alone (control) or stimulated with Fn-f 45 (1 µm) or IL-1α (10 ng/ml). IL-1Ra (10 µg/ml) was added to the cultures as indicated (j). Samples of CM were analysed for MMP-13 (i) or MMP-3 (ii) by Western blotting.
Figure 6 Fn-f 45 treatment stimulates the release of MMP-13 and MMP-3 into the media of cartilage explant cultures
Cartilage slices were cultured in serum-free media for days 1 and 2, and then stimulated with either 10 ng/ml IL-1α or 1 µM Fn-f 45 for days 3-5, or unstimulated (control). CM from cartilage explants were collected on a daily basis and resolved on SDS/10 % (w/v) polyacrylamide gels. Left panels : Western blots of MMP-13; right panels : Western blots of MMP-3.
Fn-f 45 acts to increase MMP-13 and MMP-3 expression by chondrocytes resident within the cartilage. Explants of articular cartilage were cultured serum-free for 5 days, with Fn-f 45 and IL-1α added during the last 3 days of culture. CM were harvested daily and analysed for MMPs. Western blot analyses showed that, in untreated cultures, the levels of MMP-13 decreased over the 5 day-culture period ( Figure 6, left panel) . In contrast, levels of MMP-13 protein in cultures treated with 1 µM Fn-f 45 increased over the 3 days of treatment, and were markedly higher than levels in control cultures. Maximal induction of MMP-13 was achieved with 0.5 µM Fn-f 45. Levels of MMP-3 also increased over the 3 day Fn-f 45 treatment (Figure 6, right panel) . Thus, in both the cartilage culture and the chondrocyte culture
Figure 7 Fn-f 45 treatment does not stimulate release of MMP-2 or MMP-9 into the cartilage conditioned media
Cartilage slices were cultured in serum-free media for days 1 and 2, and then stimulated with either 10 ng/ml IL-1α or 1 µM Fn-f 45 for days 3-5, or unstimulated (control). CM from cartilage explants were collected on a daily basis and resolved on SDS/7 % (w/v) polyacrylamide gels containing 0.5 mg/ml gelatin. CM from HT1080 human fibrosarcoma cells (lanes furthest to the right) were used as a positive control for the expression of gelatinases. MMP-9 in the HT1080 CM is indicated by an arrowhead, proMMP-2 by the closed arrow and active MMP-2 by the open arrow. models, Fn-f 45 was apparently as potent as IL-1α in promoting MMP-13 and MMP-3 release into the CM.
Fn-f 45 does not regulate the expression of gelatinases MMP-2 and MMP-9
The effect of Fn-f 45 treatment on the expression on the gelatinases MMP-2 and MMP-9 was analysed by zymography. Levels of the major gelatinase band at 61 kDa decreased slightly over the 5 day culture period in Fn-f 45-treated cultures (Figure 7) . Similarly, the levels of this gelatinase declined in the untreated control cultures, whereas they were maintained in the IL-1α-treated cultures (Figure 7) . Immunoprecipitation of the 61 kDa gelatinase with an anti-(MMP-2) antibody identified it as pig MMP-2 (results not shown). APMA-activation studies confirmed that the 61 kDa band corresponded to latent MMP-2 (results not shown). The faint band at 68 kDa was also immunoprecipitated by the anti-MMP-2 antibody (results not shown), suggesting that it is a glycosylated form of pig MMP-2. The faint gelatinase band at 90 kDa is most likely to be pig MMP-9. This band was not affected by treatment with Fn-f 45 or IL-1α (Figure 7) .
Analysis of aggrecan neoepitopes generated in response to Fn-f 45 treatment
To investigate whether Fn-f 45 induced the breakdown of aggrecan, the CM and tissue extracts from cartilage cultures were analysed for proteoglycan degradation, as well as the generation of specific MMP-derived and aggrecanase-derived aggrecan fragments. Fn-f 45 stimulation of cartilage slices caused a marked increase in the catabolism of aggrecan, evidenced by increased amounts of sulphated glycosaminoglycan in the CM. Approx. 45 % of the total aggrecan was degraded and released into the The 45 kDa fibronectin fragment induces MMP-13 synthesis and aggrecanase activity media after 3 days of treatment with Fn-f 45 ( Figure 8A ), compared with approx. 65 % released by IL-1α treatment and 22 % released from control cultures. In contrast, full-length fibronectin failed to stimulate proteoglycan degradation (results not shown), consistent with a report by Homandberg et al. [5] . Analysis of the CM by composite gel electrophoresis showed that treatment with Fn-f 45 resulted in fragmentation of aggrecan, generating two main fragments of faster electrophoretic mobility [shown by the arrowheads in Figure 8B, panel (i), lanes 13-15] . The pattern of fragmentation was similar to that generated by stimulation of the cartilage with IL-1α [ Figure 8B , panel (i), lanes 8-10], although IL-1α was more effective at promoting proteoglycan release ( Figure 8A) .
The aggrecan fragments in the CM were analysed for the presence of MMP-derived neoepitope using an antibody that recognizes the N-terminal amino acid sequence $%#FFGVG (numbering on the basis of the human sequence), generated by MMP cleavage of aggrecan in the interglobular domain (reviewed in [33] ). Figure 8 The presence of immunoreactivity to $%#FFGVG in control cultures suggests that MMPs are probably involved in the baseline turnover of aggrecan, as we have described recently [26] . The levels of MMP-derived $%#FFGVG fragments in the CM did not increase as a result of Fn-f 45 treatment; rather, they appeared to decrease with treatment [ Figure 8B , panel (ii), lanes [13] [14] [15] . Similarly, levels of MMPderived fragments decreased following IL-1α treatment [ Figure  8B , panel (ii), lanes [8] [9] [10] . However, because the gels were loaded on the basis of equal sulphated glycosaminoglycan in the CM, our interpretation of this experiment is that the reduced amount of $%#FFGVG immunoreactivity in response to Fn-f 45 and IL-1α treatment is consistent with increased aggrecan degradation by ADAMTS aggrecanases [26] . From the results in Figure 8 , we speculate that Fn-f 45, like IL-1α, also acts to increase the proportion of aggrecanase-derived fragments in the media. Hence, despite increased synthesis of pro-MMPs in response to Fn-f 45, the data imply that MMP cleavage of aggrecan was not stimulated.
To confirm that MMPs were not active against aggrecan in the Fn-f 45-stimulated cultures, the tissue extracts were examined by Western blotting for the presence of G1-domain fragments containing the C-terminal DIPEN$%" neoepitope (reviewed in [33] ). These fragments remain anchored within the tissue by interaction between the G1 domain and hyaluronan. Western blotting of GdmCl extracts using anti-DIPEN$%" antibody showed that Fn-f 45 treatment did not alter the levels of this fragment significantly (Figure 9, top panel) . Densitometric analysis of four experiments showed that levels of DIPEN$%" neoepitope were 0.6-1.7-fold greater in Fn-f 45-treated cultures than in untreated cultures, which was considered an insignificant difference. We tested next whether aggrecanase activity was stimulated by Fn-f 45, by examining GdmCl extracts for the presence of G1-containing ITEGE$($ epitope. This fragment is generated by aggrecanases and remains bound within the tissue. Fn-f 45 significantly up-regulated the levels of ITEGE$($ epitope in the extracts (Figure 9 , bottom panel). Densitometric analysis of six experiments showed that levels of ITEGE$($ were 2-14-fold greater in Fn-f 45-treated cultures in comparison with untreated cultures. To confirm that this epitope was not generated by the intrinsic enzymic activity of fibronectin fragments [6] , biologically inactive, freeze-thawed cartilage was substituted for live cartilage in explant cultures. In these experiments, levels of ITEGE$($ epitope were low, and similar in both Fn-f 45-treated and untreated cultures (results not shown). In summary, the neoepitope studies supported our hypothesis that the breakdown of aggrecan in Fn-f 45-stimulated cartilage cultures was mainly as a result of aggrecanase action.
DISCUSSION
We describe here that Fn-f 45 stimulates the synthesis of MMP-13 in cartilage, the first report to show that MMP-13 is regulated by a fragment of fibronectin. Evidence from studies with selective collagenase inhibitors suggests that MMP-13 has a major role in the degradation of type II collagen in osteoarthritic cartilage [14] . MMP-13 is also effective at cleaving aggrecan [34] , hence localized increases in the collagen-binding fragment of fibronectin in arthritic cartilage may have the potential to exacerbate disease by regulating enzymes that are capable of degrading these key structural molecules.
Our studies showed that Fn-f 45 also increased the synthesis of MMP-3. Similar results were reported for Fn-f 29, which stimulated MMP-3 synthesis by bovine chondrocytes in culture [35] . However, Fn-f 29 also stimulated MMP-2 release by explant cultures of human cartilage that were cultured serum-free [8] . We found no evidence to suggest that either of the gelatinases were regulated by Fn-f 45 in our pig cartilage culture model. Analysis of the GdmHCl extracts for the membrane-bound MT1-MMP (MMP-14) also showed that the protein levels of this enzyme were unaffected by Fn-f 45 (H. Stanton and A. J. Fosang, unpublished work). Hence Fn-f 45 regulates specific members of the MMP family only.
On the basis of previously published studies, we hypothesized that IL-1 might be an important mediator in the regulation of MMPs-13 and -3 by Fn-f 45. Reports have shown that Fn-fs encompassing the RGD integrin-binding site regulate the synthesis of MMPs via an IL-1 autocrine loop [9, 36] . Other regions of fibronectin also signal via IL-1, with Fn-f-29-induced MMP-3 release in cartilage cultures partially blocked by IL-1-neutralizing antibodies [10] . However, our studies using IL-1Ra showed that IL-1Ra failed to inhibit Fn-f 45-stimulated MMP-13 and MMP-3 production, even at concentrations sufficient to block induction of these MMPs by exogenously added IL-1α. It therefore appears that Fn-f 45 acts independently of IL-1, indicating specific signalling pathways for the different fragments of fibronectin.
MMP-13 and MMP-3 were detected in the latent form only, in both chondrocyte and cartilage culture models. Neither Fn-f 45 nor IL-1α, a key cytokine in cartilage degradation, stimulated the conversion of MMP-13 and MMP-3 into their respective active forms. Although the precise mechanisms for MMP-13 and MMP-3 activation in i o are not known, activation of MMP-3 in itro has been attributed to cell-surface-associated plasmin [37] . Active MMP-3 can in turn activate MMP-13 as part of an MMPdriven activation cascade. Alternatively, studies in itro have implicated cell-surface MT1-MMP (MMP-14) and active MMP-2 in the activation of MMP-13 [38] . Clearly these activation mechanisms were not operating in the cartilage and chondrocyte culture models. Our preliminary studies showed that, although Fn-f 29 and Fn-f 120 (cell-binding domain of fibronectin) increased MMP-13 and MMP-3 synthesis, they failed to initiate MMP activation (H. Stanton and A. J. Fosang, unpublished work), in contrast with a study by Homandberg and Hui [8] , who detected active MMP-3 in explant cultures of human cartilage treated with Fn-f 29.
Our observation that MMPs-13, -3, -2 and -9 were not in the active form was consistent with the observation that Fn-f 45 did not increase MMP-derived aggrecan neoepitopes. Although Fn-f 45 clearly stimulated aggrecan fragmentation in this study, levels of MMP-derived DIPEN$%" neoepitopes in cartilage did not increase significantly, indicating a lack of MMP activity. The lack of MMP activity was not due to the serum-free culture conditions, since incubation of cartilage explants for 3 days in serum before stimulation also failed to increase levels of DIPEN$%" neoepitope. Measurement of the $%#FFGVG N-terminal fragment of aggrecan in CM supported the conclusion that Fn-f 45 did not stimulate MMP activity. The data showed that the proportion of MMP-derived $%#FFGVG fragments present in the media appeared to decrease in response to Fn-f 45 stimulation, consistent with a rise in the level of aggrecan catabolism by non-MMP proteinases. We have shown that stimulation of cartilage explants with IL-1α and retinoic acid elicits a similar pattern of $%#FFGVG fragment release [26] . Hence Fn-f 45 potentially has a dual role in the breakdown of cartilage, promoting both increased synthesis of MMPs as well as the breakdown of aggrecan by an MMP-independent mechanism.
The combined observations that proteoglycan release was elevated in response to Fn-f 45, but that MMP activity was not apparent, led us to compare the levels of the aggrecanase-derived ITEGE$($ epitope in control and treated cartilage. After 3 days of Fn-f 45 treatment, ITEGE$($ levels in GdmHCl extracts were significantly increased. Thus Fn-f 45, like Fn-f 29 [39, 40] , acts to increase cleavage of aggrecan at the ITEGE$($ A$(%RGSV sequence in the interglobular domain. Our data gave no indication of which member(s) of the ADAMTS family were regulated. Of the mammalian ADAMTS family members identified to date, ADAMTS-4 (aggrecanase-1) and ADAMTS-5 (aggrecanase-2; ADAMTS-11) are thought to be the major proteinases responsible for cleavage at the ITEGE$($ A $(%RGSV site in aggrecan [17, 18] . mRNA transcripts for ADAMTS-4 and -5 have been detected in articular cartilage [41] , with ADAMTS-1 and ADAMTS-4 highly expressed in arthritic joint tissues [17] . Our future studies will address whether Fn-f 45 regulates members of the ADAMTS family. At present it is difficult to predict the outcome of these studies, since regulation of ADAMTS-4 and -5 mRNA by inflammatory mediators is both species-specific and age-specific [41] . Furthermore, it appears that ADAMTS expression and activity may be regulated by transcriptional and post-transcriptional mechanisms, and that regulation is tissuespecific [42, 43] .
Our findings corroborate mounting evidence implicating fragments of fibronectin in the destruction of articular cartilage. In addition to Fn-f 45, other studies have shown that Fn-f 29, the cell-binding domain of fibronectin, and RGD peptides all increase MMP synthesis by chondrocytes [9, 35] . Similarly, it appears that Fn-f 29 [39, 40] and Fn-f 45 also regulate degradation of aggrecan by aggrecanases. The challenge is now to determine the pathways by which these diverse regions of fibronectin direct metalloproteinase expression. Work with other cell types has provided valuable information, particularly regarding the cellbinding domain of fibronectin, which signals via the RGD sequence in type III repeat 10 (see Figure 1) . A number of integrins recognize this site, including α5β1, αvβ1, αvβ3 and αvβ5 integrins. Werb et al. [44] showed that the cell-binding fragment up-regulates the expression of MMPs-1 and -3 by synovial fibroblasts, via α5β1 integrin. A further, well-delineated study by this group described a sequence of events in which soluble ligands of the α5β1 integrin stimulated the GTP-binding protein Rac1, which, in turn, promoted nuclear factor-κB-dependent transcription of IL-1, followed by IL-1-induced up-regulation of MMP-1 [36] .
However, Fn-f 45 does not contain sequences similar to RGD, and is therefore unlikely to bind to the active site of the α5β1 integrin. Despite the lack of an RGD sequence, it has been suggested that N-terminal Fn-fs initiate cell signalling via integrins [1, 45] . In support of this concept, Akimov et al. [46] have demonstrated complexes between the 42 kDa gelatinbinding fragment of fibronectin (essentially Fn-f 45), β1 or β3 integrin subunits and cell-surface tissue transglutaminase (tTG). They showed that fibroblasts transfected with tTG adhered to culture plastic-coated with 42 kDa Fn-f, and formed focal adhesions, signalling tyrosine phosphorylation via integrins. They speculated that high-affinity interactions between 42 kDa Fn-f and tTG might provide supplementary sites for cellular interaction with fibronectin, in addition to interactions between the cell-binding domain and integrins. Given that chondrocytes express tTG, the study by Akimov et al. [46] presents several possibilities for Fn-f 45 signalling. First, Fn-f 45 might initiate integrin signalling directly, via complexes with tTG. Alternatively, Fn-f 45 might disrupt interactions between full-length fibronectin and tTG, thus altering signals arising from fibronectin. Other potential signalling mechanisms for N-terminal Fn-fs have been reviewed [1] .
In summary, we have described that Fn-f 45 has the potential to exacerbate cartilage degradation in arthritis, by increasing expression of MMPs. The addition of Fn-f 45 to cartilage in culture induced the synthesis of MMP-13 and MMP-3 specifically, via an IL-1-independent mechanism. Fn-f 45 also promoted aggrecan degradation by aggrecanases, but failed to promote aggrecan degradation by MMPs. Moreover, the MMPs detected in cartilage cultures were exclusively in the latent form. We speculate that, in the more complex environment of the arthritic joint, MMPs might be activated following induction by Fn-f 45, and might contribute to MMP-mediated collagen degradation. However, collagen degradation would be expected at a time point later than aggrecanolysis [41] . Given that MMPs can act on fibronectin to release fibronectin fragments [31, 47] , there is potential for an increasing cycle of cartilage damage as Fn-f concentrations rise. Understanding the pathways by which various Fn-fs signal increased enzyme activity is essential for the design of therapies aimed at limiting proteolytic damage to cartilage macromolecules.
